---

---

Eli Lilly and Company

LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

(0.0% 1d) (-5.4% 1m) (90.8% 1y) (0.0% 2d) (0.0% 3d) (-2.6% 7d) (-32.85% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 694,883,768,681
http://www.lilly.com
Sec Filling | Patents | 33625 employees


(US) Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Drugs

Alimta (Pemetrexed disodium)
Amyvid (Florbetapir F 18)
Bamlanivimab (Bamlanivimab)
Baqsimi (glucagon)
BASAGLAR KwikPen (Insulin glargine)
BASAGLAR Tempo Pen (Insulin glargine)
Cialis (Tadalafil)
Cymbalta (Duloxetine hydrochloride)
CYRAMZA (ramucirumab)
Effient (Prasugrel hydrochloride)
EMGALITY (galcanezumab-gnlm)
Etesevimab (Etesevimab)
Evista (Raloxifene hydrochloride)
Forteo (Teriparatide)
Gemzar (Gemcitabine hydrochloride)
Glucagon (glucagon)
Humalog (Insulin lispro)
Humalog Junior KwikPen (Insulin lispro)
Humalog KwikPen (Insulin lispro)
Humalog Mix50/50 (Insulin lispro)
Humalog Mix50/50 KwikPen (Insulin lispro)
Humalog Mix75/25 (Insulin lispro)
Humalog Mix75/25 KwikPen (Insulin lispro)
Humalog Tempo Pen (Insulin lispro)
HUMATROPE (Somatropin)
Humulin 70/30 (Insulin human)
Humulin 70/30 KwikPen (Insulin human)
Humulin N (Insulin human)
Humulin R (Insulin human)
Humulin R U-500 (Insulin human)
Humulin R U-500 KwikPen (Insulin human)
Insulin Lispro (Insulin lispro)
Insulin Lispro Junior KwikPen (Insulin lispro)
Insulin Lispro KwikPen (Insulin lispro)
Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (Insulin lispro)
LARTRUVO (olaratumab)
LYUMJEV (Insulin lispro-aabc)
LYUMJEV Junior KwikPen (Insulin lispro-aabc)
LYUMJEV KwikPen (Insulin lispro-aabc)
LYUMJEV Tempo Pen (Insulin lispro-aabc)
Olumiant (baricitinib)
Portrazza (necitumumab)
RETEVMO (selpercatinib)
Reyvow (lasmiditan)
Sterile Diluent (diluent)
Strattera (Atomoxetine hydrochloride)
Symbyax (Olanzapine and Fluoxetine hydrochloride)
TALTZ (ixekizumab)
TAUVID (Flortaucipir F-18)
Trulicity (Dulaglutide)
Verzenio (abemaciclib)
Zyprexa (Olanzapine)
ZYPREXA Intramuscular (Olanzapine)
ZYPREXA Relprevv (Olanzapine pamoate)
ZYPREXA Zydis (Olanzapine)

add to watch list Paper trade email alert is off

---

Press-releases

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
Published: 2024-04-22 (Crawled : 21:00) - globenewswire.com
PRQR | News | $2.015 1.26% 1.24% 110K |

Health Technology

| Email alert Add to watchlist
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| Email alert Add to watchlist
meeting

---

Peptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 15:00) - prnewswire.com
AZNCF | News | $136.2 -4.19% 1.7K |

Health Technology

| 2.53% | O: 0.24% H: 0.42% C: 0.42%
NVO | News | $125.26 2.08% 0.18% 3.6M |

Health Technology

| 0.59% | O: -0.84% H: 0.86% C: -0.62%
GSK | News | $40.59 2.11% -0.36% 3.8M |

Health Technology

| 2.5% | O: -0.56% H: 0.0% C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| -2.59% | O: -0.21% H: 0.11% C: -3.05%
AZN | News | $70.12 2.29% 2.24% 4.8M |

Health Technology

| 2.73% | O: -0.18% H: 0.84% C: 0.6%
report reach therapeutics market

---

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Published: 2024-04-17 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| 0.0% | O: 0.0% H: 0.0% C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M |

Health Technology

| -0.16% | O: -1.81% H: 0.0% C: 0.0%
biotech

---

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Published: 2024-04-17 (Crawled : 11:00) - biospace.com/
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| -2.68% | O: 1.03% H: 1.66% C: -1.11%
obesity tirzepatide

---

Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Published: 2024-04-16 (Crawled : 15:00) - biospace.com/
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| -2.59% | O: 0.09% H: 0.0% C: 0.0%
announcement conference for financial results

---

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
Published: 2024-04-15 (Crawled : 20:00) - globenewswire.com
CRGX | $19.06 -0.68% -0.68% 260K |

| -4.32% | O: -1.76% H: 6.0% C: 2.35%
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| -2.59% | O: 0.09% H: 0.0% C: 0.0%
BDTX | $5.02 -4.56% -4.78% 510K |

Health Technology

| -3.83% | O: 0.57% H: 2.86% C: 2.48%
AUTL | $4.58 1.33% 1.31% 1.2M |

Health Technology

| -6.94% | O: 0.0% H: 2.04% C: -0.82%
therapeutics

---

Usher Syndrome Market to Exhibit Growth at a CAGR of 10.55% by 2034 | DelveInsight
Published: 2024-04-11 (Crawled : 22:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -5.8% | O: -100.0% H: NaN% C: Infinity%
ALPMY | News | $9.5 -1.11% 1M |

Manufacturing

| -7.39% | O: -8.65% H: 3.19% C: 1.6%
JNJ | News | $149.12 0.82% 0.0% 9.3M |

Health Technology

| -1.05% | O: -1.65% H: 0.0% C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| -3.72% | O: -0.0% H: 0.52% C: -1.04%
growth market

---

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| -2.73% | O: 1.06% H: 0.47% C: -0.03%
fda device disease test granted blood designation for alzheimer's roche

---

Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| -3.42% | O: -0.71% H: 0.0% C: 0.0%
drug preclinical meeting

---

Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
Published: 2024-04-09 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -1.65% | O: -0.01% H: 0.0% C: 0.0%
TMO | News | $548.38 0.66% 0.29% 1.5M |

Health Technology

| -6.93% | O: -2.01% H: 0.0% C: 0.0%
LLY | News | $731.33 0.69% 0.0% 2.3M |

Health Technology

| -3.42% | O: -0.71% H: 0.0% C: 0.0%
BIO | $280.13 0.14% 0.0% 180K |

Health Technology

| -17.48% | O: -2.71% H: 0.52% C: 0.24%
AVTR | $24.41 1.29% 0.0% 5.5M |

Process Industries

| -5.61% | O: -1.7% H: 1.08% C: 0.55%
THMO | $0.621 -6.28% -6.7% 12K |

Health Technology

| -21.81% | O: 4.99% H: 2.78% C: -2.1%
SNY | News | $47.125 1.78% 1.75% 2.1M |

Health Technology

| -2.64% | O: -0.32% H: 0.0% C: 0.0%
global growth market

---

See all

---

Your Today's Watch List

Sign in to create a watchlist

---

Gainers vs Losers

75%

25%

Top 10 Gainers

MTTR | News M | $4.78 174.71% 63.6% 72M |

AGBA | $2.565 105.2% 51.27% 200M |

Finance

MLEC | $2.44 74.29% 42.62% 78M |

n/a

EDBL | News | $6.28 67.02% 40.13% 16M |

ATGL | $2.91 48.81% 32.8% 180K |

ZAPP | $0.2175 47.16% 32.05% 16M |

n/a

ONFO | $0.6075 38.38% 27.74% 7.3M |

n/a

VIVK | $1.48 38.32% 27.7% 530K |

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.8M |

SDIG A | $3.635 35.13% 26.0% 1M |

---

Last 48 Hours Insiders Buying

MCFT P 26039 | $21.5 1.9% 1.86% 110K |

Consumer Durables

| 00:00
YORW P 29 | $35.43 1.03% 1.02% 66K |

Utilities

| 19:01
VUZI P 14500 | $1.35 11.57% 10.37% 890K |

Electronic Technology

| 17:00
BANF P 256 | $91.28 2.24% 2.18% 150K |

Finance

| 15:30
RMCF | $3.56 0.28% 0.28% 11K |

Consumer Non-Durables

| 20:10

---

12 months watchlist earnings calendar

---